Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: A retrospective cross-sectional analysis

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Capdevila, Jaume ^a   Sevilla, Isabel ^b   Alonso, Vicente ^c   Antón Aparicio, Luís ^d   Fonseca, Paula Jiménez ^e   Grande, Enrique ^f   Reina, Juan José ^g   Manzano, José Luís ^h   Alonso Lájara, Juan Domingo ⁱ   Barriuso, Jorge ^j   Castellano, Daniel ^k   Medina, Javier ^l   López, Carlos ^m   Segura, Ángel ⁿ   Carrera, Sergio ^o   Crespo, Guillermo ^p   Fuster, José ^q   Munarriz, Javier ^r   García Alfonso, Pilar ^s  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e Asturias Central University Hospital   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^l HOSPITAL VIRGEN DE LA SALUD   (Spain)

^m HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^o HOSPITAL DE CRUCES   (Spain)

^p HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^q HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^r Castellon Provincial Hospital   (Spain)

^s HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

more..

Author keywords

Clinical practice; Combination treatment; Cross sectional analysis; Everolimus; Lanreotide; Neuroendocrine tumours; Somatostatin analogues; Sunitinib

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; SOMATOSTATIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EPISTAXIS; FEMALE; HAND FOOT SYNDROME; HEADACHE; HOSPITAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL EDEMA; PNEUMONIA; PRIMARY TUMOR; PROBABILITY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SPAIN; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMORS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PEPTIDES, CYCLIC; RETROSPECTIVE STUDIES; SOMATOSTATIN; YOUNG ADULT;

EID: 84938741676     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1512-6     Document Type: Article

References (26)

1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1-18. vii.
2. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6-32.
3. Phan AT, Oberg K, Choi J, Harrison Jr LH, Hassan MM, Strosberg JR, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010;39(6):784-98.
4. Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17(3):49-64.
5. Garcia-Carbonero R, Salazar R, Sevilla I, Isla D. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS). Clin Transl Oncol. 2011;13(8):545-51.
6. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. Pless: SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31(11):1133-40.
7. Murphy WA, Lance VA, Moreau S, Moreau JP, Coy DH. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Life Sci. 1987;40(26):2515-22.
8. Culler MD, Oberg K, Arnold R, Krenning EP, Sevilla I, Diaz JA. Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 Suppl 1:9-17.
9. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-63.
10. Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17(6):747-55.
11. Massuti B, Alonso V, Mármol M, Castellano D, Fonseca E, Velasco A, et al. Evaluation of the efficacy and the safety of lanreotide on tumour growth stabilization in patients with progressive neuroendocrine tumours (NETs) who are not eligible to be treated with either surgery or chemotherapy - TTD Group Study. Eur J Cancer. 2011;47 suppl 1:480-1.
12. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláĉková E, et al; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-33.
13. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005-12.
14. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-13.
15. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-23.
16. Benavent M, de Miguel MJ, Garcia-Carbonero R. New targeted agents in gastroenteropancreatic neuroendocrine tumors. Target Oncol. 2012;7(2):99-106.
17. Vinik A, Van Cutsem E, Niccoli P, Raoul JL, Bang YJ, Borbath I, et al. Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET). J Clin Oncol. 2012;30:abstr 4118.
18. Bousquet C, Lasfargues C, Chalabi M, Billah SM, Susini C, Vezzosi D, et al. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy. J Clin Endocrinol Metab. 2012;97(3):727-37.
19. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69-76.
20. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311-8.
21. Fonseca PJ, Uriol E, Galván JA, Álvarez C, Pérez Q, Villanueva N, et al. Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. Case Rep Oncol. 2013;6(2):441-9.
22. Castellano D, Grande E, Barriuso J. Advances in pancreatic neuroendocrine tumor treatment. N Engl J Med. 2011;364(19):1872-3. author reply 1873-1874.
23. Barriuso J, Grande E, Quindós Varela M, Sereno M, López C, Sepulveda J, et al. Sunitinib efficacy and tolerability in patients with neuroendocrine tumors out of a trial: a Spanish Multicenter Cohort. Ann Oncol. 2010;21 suppl 8:viii264 abstr 847P.
24. Shah MH, Lombard-Bohas C, Ito T, Wolin EM, Van Cutsem E, Sachs C, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-3). J Clin Oncol. 2011;29(suppl):abstr 4010.
25. Valle J, Faivre S, Raoul J, Bang Y, Patyna S, Lu DR, et al. Phase III trial of sunitinib versus placebo for treatment of pancreatic neuroendocrine tumors: impact of somatostatin analogue treatment on progression-free survival. Ann Oncol. 2010;21 suppl 8:viii264 abstr 846P.
26. Raymond E, Faivre S. Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours. Curr Oncol. 2014;21(6):309-17.